期刊文献+

N-乙酰半胱氨酸对子宫颈癌细胞紫杉醇耐药性的影响

Effects of N-acetylcysteine on resistance to paclitaxel in cervical carcinoma cells
原文传递
导出
摘要 目的建立耐紫杉醇(PTX)子宫颈癌细胞株,观察N-乙酰半胱氨酸(NAC)对子宫颈癌细胞紫杉醇耐药的影响。方法用PTX处理并培养Hela细胞,建立耐PTX子宫颈癌细胞株Hela/PTX。观察和检测其细胞形态、细胞生长曲线、耐药指数、氧化还原状态及紫杉醇耐药基因1(Txr1)的表达。用NAC处理Hela/PTX细胞,观察NAC对其PTX耐药的影响。结果用PTX处理Hela细胞10个月后,可获得在500μg/L PTX中生长状态良好的Hela/PTX细胞。Hela/PTX细胞体积偏大,胞浆内颗粒较多,群体倍增时间是亲代细胞的1.32倍,对PTX具有显著耐药性,耐药指数为122.69。与Hela细胞相比,Hela/PTX细胞有高水平的活性氧(ROS)和Txr1 mRNA,但还原型谷胱甘肽(GSH)水平及超氧化物歧化酶、过氧化氢酶和谷胱甘肽过氧化物酶活性却有不同程度的降低,而氧化型谷胱甘肽(GSSG)水平和GSH/GSSG比值则无明显变化。NAC处理后,Hela/PTX细胞ROS和Txr1mRNA水平下降,对PTX敏感性增加。结论耐紫杉醇Hela/PTX细胞氧化还原状态失衡,Txr1表达增加。NAC能降低ROS水平,减少Txr1表达,可逆转其对PTX的耐受。 Objective To construct a paclitaxel (PTX)-resistant human cervical carcinoma cell line and observe the effects of N-acetylcysteine (NAC) on resistance to PTX in the cells. Methods Hela cells were treated with PTX to construct the PTX-resistant Hela/PTX cell line. The cell shape, cell growth curves and drug resistance index as well as the cellular redox state and the taxol resistance gene 1 (Txr1) expression were observed or determined. Hela/PTX cells were treated with NAC, and the effects of NAC on resistance to PTX in the cells were observed. Results After Hela cells were treated with PTX for 10 months, the PTX-resistant cervical carcinoma Hela/PTX cells could be obtained, which grew well in 500μg/L of PTX. Compared with Hela cells, the size of Hela/PTX cells was larger, and there were more cytoplasmic granules in them. The population doubling time for Hela/PTX cells was 1.32 times of that for Hela cells. Hela/PTX cells manifested a stronger resistance to PTX than Hela cells did with the resistance index of 122.69. They had higher levels of reactive oxygen species (ROS) and Txr1 mRNA, a lower level of reduced glutathione(GSH), and lower activities of superoxide dismutase, catalase and glutathione peroxidase than Hela cells. There was no significant difference between Hela/PTX and Hela cells in the level of oxidized glutathione (GSSG) or the GSH to GSSG ratio. After Hela/PTX cells were treated with NAC, the levels of ROS and Txr1 mRNA in them decreased, and they were more sensitive to PTX. Conclusion In Hela/PTX cells, which resisted to PTX, there was a redox imbalance, and the Txr1 transcripts increased. NAC could reduce the levels of ROS and Txrl mRNA in Hela/PTX cells and reversed the sensitivity of them to PTX.
出处 《山东大学学报(医学版)》 CAS 北大核心 2013年第3期42-47,共6页 Journal of Shandong University:Health Sciences
基金 山东省优秀中青年科学家科研奖励基金(2008BS03038)
关键词 子宫颈肿瘤 紫杉醇 抗药性 N-乙酰半胱氨酸 活性氧 紫杉醇耐药基因1 Cervical neoplasms Paclitaxel Drug resistance N-acetylcysteine Reactive oxygen species Taxol resistance gene 1
  • 相关文献

参考文献3

二级参考文献25

  • 1Yan, Feng,Wang, Xiao-Min,Liu, Zhong-Chen,Pan, Chao,Yuan, Si-Bo,Ma, Quan-Ming.JNK1,JNK2,and JNK3 are involved in P-glycoprotein-mediated multidrug resistance of hepatocellular carcinoma cells[J].Hepatobiliary & Pancreatic Diseases International,2010,9(3):287-295. 被引量:14
  • 2关云艳,欧希龙,郭庆明,颜芳.P-gp,ToPoⅡ和GST-π在胃癌组织中的表达及与预后的关系[J].世界华人消化杂志,2006,14(35):3371-3376. 被引量:21
  • 3Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study [J ]. J Clin Oncol, 2004, 22 (15 ): 3113-3119.
  • 4Homesley HD, Meltzer NP, Nieves L, et al. A phase Ⅱ trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer [J ]. Int J Clin Oncol, 2008, 13 (1): 62-65.
  • 5Jain RK, Kirar P, Gupta G, et al. A comparative study of low dose weekly paclitaxel versus cisplatin with concurrent radiation in the treatment of locally advanced head and neck cancers [J ]. Indian J Cancer, 2009, 46( 1 ): 50-53.
  • 6Benedetti Panici P, Bellati F, Manci N, et al. Neoadjuvant chemotherapy followed by radical surgery in patients affected by FIGO stage ⅣA cervical cancer [J]. Ann Surg Oncol, 2007, 14 (9): 2643-2648.
  • 7Moore KN, Herzog TJ, Lewin S, et al. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage ⅣB, recurrent or persistent cervical cancer [J ]. Gynecol Oncol, 2007, 105 (2): 299-303.
  • 8Mabuchi S, Morishige K, Fujita M, et al. The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy [J ]. Gynecol Oncol, 2009, 113 (2): 200-204.
  • 9Secord AA, Havrilesky LJ, C.arney ME, et al. Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer [J ]. Int J Clin Oncol, 2007, 12 ( 1 ): 31-36.
  • 10Mori T, Hosokawa K, Kinoshita Y, et al. Neoadjuvant chemotherapy with weekly carboplatin and paclitaxe| for locally advanced cervical carcinoma [ J ]. Int J Gynecol Cancer, 2008, 18 ( 1 ): 85-89.

共引文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部